Written by the Nuvirox Research Team
KEY POINTS
- Multiple randomized trials confirm oral NR raises whole-blood NAD+ dose-dependently.
- This is one of the better-replicated facts in the field — the biomarker really does move.
- Whether a higher NAD+ reading produces benefits you'd notice is a separate, less settled question.
Short answer: yes, the biomarker rises — that part is well established. If the question is narrowly "do oral NAD+ precursors increase the amount of NAD+ measurable in your body," the randomized human evidence is genuinely solid and repeated across labs. The honest caveat is that raising the number and changing how you feel are two different claims, and only the first is well evidenced.
What counts as proof here?
The cleanest evidence is a randomized, placebo-controlled trial that measures NAD+ (or its metabolites) in blood or tissue before and after supplementation. Several exist for nicotinamide riboside, and they line up.
The crossover benchmark. In a 2018 randomized, double-blind, placebo-controlled crossover trial, 30 healthy middle-aged and older adults took 500 mg NR twice daily for six weeks. NR was well tolerated and effectively stimulated NAD+ metabolism — a clean demonstration that the precursor does what it claims at the biomarker level.
STUDY SNAPSHOT
| Design | Randomized, double-blind, placebo-controlled crossover |
| Participants | 30 healthy adults aged 55–79 |
| Intervention | 500 mg NR twice daily, 6 weeks |
| Result | NAD+ metabolism significantly elevated; well tolerated |
The dose-response. A separate randomized trial in overweight adults showed 100, 300, and 1000 mg of NR raised whole-blood NAD+ by roughly 22%, 51%, and 142% within two weeks — a textbook dose-dependent curve, which is exactly what you'd want to see if the effect is real and not noise.
Into the muscle. Work in older adults showed NR supplementation augmented the NAD+ metabolome in aged skeletal muscle and shifted anti-inflammatory signatures — evidence the rise isn't confined to blood but reaches tissue.
So why the skepticism?
Because "raises NAD+" gets quietly stretched into "reverses aging" or "restores your energy," and those are not the same claim. A careful review of the human NR literature — covering around 25 published trials — makes the point that while NAD+ elevation is well supported, many downstream benefit claims are not yet well founded. The biomarker is the strong part of the story; the life-changing outcomes are the weak part.
The honest null. In obese men, NR raised NAD+ metabolites but didn't improve insulin sensitivity or body composition over twelve weeks. Clear biomarker movement, no change in the metabolic outcomes measured. That study is essential context: a real NAD+ rise does not automatically cash out as a benefit you'd value.
Does everyone respond the same?
Roughly, yes for the biomarker — the NAD+ rise is fairly reliable. But functional effects appear to cluster in people who started lower, often older adults, where there's more headroom. If you want to understand the lag between the blood change and any felt change, see how long NAD+ takes to work.
What this means for choosing a supplement
It means the precursor matters. The dose-response evidence is strongest for nicotinamide riboside at doses in the hundreds-of-milligrams range used in trials. A product delivering a trial-relevant NR dose has a real basis for the "raises NAD+" claim; a sprinkle of unproven ingredients dressed up as an "NAD booster" does not. For how to evaluate a label, see how to choose the best NAD+ supplement.
Blood NAD+ versus tissue NAD+
Here's a subtlety the marketing usually skips: most human trials measure NAD+ in whole blood or in peripheral blood mononuclear cells, because that's what's accessible. What we'd often most like to know — NAD+ levels inside muscle, brain, or other specific tissues — is far harder to sample and much less frequently reported. Elhassan and colleagues did examine the aged skeletal-muscle NAD+ metabolome and found NR shifted it, which is genuinely informative, but the broader pattern is that “it raises NAD+” most often means “it raises measurable blood NAD+.” That's real and worth knowing, but it's not identical to proving every tissue you care about is repleted in proportion.
Why the rise doesn't guarantee a result
Raising NAD+ is necessary but not sufficient for a clinical benefit. Several well-run trials raised NAD+ convincingly and still found no improvement in the outcome being measured — Dollerup's work in obese men is the textbook example, where NAD+ went up but insulin sensitivity and body composition didn't budge. This is the most important honesty check in the whole category: a biomarker moving is the beginning of a question, not the end of one. When you see “clinically proven to raise NAD+,” read it precisely — it usually means exactly that and nothing more.
It's also worth knowing that NAD+ measurement methods vary between labs, which makes cross-study comparison harder than it looks. A percentage rise reported in one trial isn't always directly comparable to another that used a different assay or sample type. None of this means the increases aren't real — the direction of effect is consistent — but it's a reason to focus on the weight of the evidence rather than fixating on any single headline percentage.
Frequently asked questions
Do NAD+ supplements really raise NAD+?
On the evidence, yes — oral nicotinamide riboside raises whole-blood NAD+ dose-dependently across multiple randomized trials. It's one of the better-replicated findings in the field.
If NAD+ goes up, why might I not feel different?
Because a higher biomarker doesn't automatically change function. Some trials show benefits (often in older or deficient people); others show the NAD+ rise with no change in the outcome measured.
Which precursor has the best evidence for raising NAD+?
Nicotinamide riboside (NR) has the most consistent randomized human data showing a dose-dependent NAD+ rise.
Can I get my NAD+ levels tested?
Some labs offer NAD+ testing, but interpretation is tricky and it isn't a routine clinical test. For most people it isn't necessary to benefit from — or to evaluate — a precursor.
From Nuvirox
Why we formulated NAD+ Restore
NAD+ Restore is built around 500 mg of Nicotinamide Riboside Chloride (NR) per two-capsule serving — one of the two most-researched NAD+ precursors, within the dose range used in published human trials. We pair it with 150 mg trans-resveratrol (from Japanese Knotweed) and 50 mg quercetin (from Sophora japonica), polyphenols studied alongside NAD+ pathways for cellular health support, plus 10 mg galactomannans from fenugreek to support absorption.
It ships with a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
Learn more about NAD+ Restore →The bottom line
On the narrow, testable question — do oral precursors raise NAD+? — the answer from randomized human trials is a confident yes, especially for nicotinamide riboside. Just keep the two claims separate: raising the biomarker is well proven; turning that into benefits you'd notice is real for some people, absent for others, and still being worked out.
References
- Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. PMID: 29599478. DOI: 10.1038/s41467-018-03421-7.
- Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019;9:9772. PMC: PMC6611812. DOI: 10.1038/s41598-019-46120-z.
- Elhassan YS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019;28(7):1717–1728.e6. DOI: 10.1016/j.celrep.2019.07.043.
- Dollerup OL, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343–353. DOI: 10.1093/ajcn/nqy132.
- Sharma A, et al. What is really known about the effects of nicotinamide riboside supplementation in humans. Sci Adv. (review of 25 human NR trials). DOI: 10.1126/sciadv.adi4862.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.